Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Assets (2022 - 2025)

Gossamer Bio's Assets history spans 4 years, with the latest figure at $172.2 million for Q4 2025.

  • For Q4 2025, Assets fell 45.37% year-over-year to $172.2 million; the TTM value through Dec 2025 reached $172.2 million, down 45.37%, while the annual FY2025 figure was $172.2 million, 45.37% down from the prior year.
  • Assets reached $172.2 million in Q4 2025 per GOSS's latest filing, down from $208.8 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $373.4 million in Q2 2024 to a low of $172.2 million in Q4 2025.
  • Average Assets over 4 years is $275.0 million, with a median of $276.5 million recorded in 2022.
  • Peak YoY movement for Assets: surged 105.48% in 2024, then plummeted 45.37% in 2025.
  • A 4-year view of Assets shows it stood at $272.4 million in 2022, then increased by 14.49% to $311.9 million in 2023, then increased by 1.08% to $315.3 million in 2024, then tumbled by 45.37% to $172.2 million in 2025.
  • Per Business Quant, the three most recent readings for GOSS's Assets are $172.2 million (Q4 2025), $208.8 million (Q3 2025), and $240.9 million (Q2 2025).